Filtered By:
Condition: Pulmonary Thromboembolism
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 138 results found since Jan 2013.
Temporal trends of case-fatality in patients undergoing dual-injection coronary chronic total occlusion recanalization
ConclusionAnnual number of CTO procedures performed in Germany increased from 2009 to 2020 with a concomitant anti-proportional decrease in the case-fatality. Our findings may help to draw more attention to predictors of in-hospital case fatality in patients hospitalized for CTO recanalization.Graphical abstract
Source: Clinical Research in Cardiology - September 11, 2023 Category: Cardiology Source Type: research
Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery
CONCLUSIONS: In some types of elective surgery, cell salvage may reduce the need for and volume of allogeneic transfusion, alongside evidence of no difference in adverse events, when compared to no cell salvage. Further research is required to establish why other surgeries show no benefit from CS, through further analysis of the current evidence. More large RCTs in under-reported specialities are needed to expand the evidence base for exploring the impact of CS.PMID:37681564 | PMC:PMC10486190 | DOI:10.1002/14651858.CD001888.pub5
Source: Cochrane Database of Systematic Reviews - September 8, 2023 Category: General Medicine Authors: Thomas D Lloyd Louise J Geneen Keeley Bernhardt William McClune Scott J Fernquest Tamara Brown Carolyn Dor ée Susan J Brunskill Michael F Murphy Antony Jr Palmer Source Type: research
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases —a phase II study
ConclusionsPanitumumab and FOLFIRI as perioperative therapy for resectable CLM result in a radiological objective response rate in 65.7% of patients with a manageable grade 3 diarrhea rate of 14.3%. Median PFS was 13.2 months, and the 24-month OS rate was 73.3%. These data are insufficient to widen the indication of panitumumab from the unresectable setting to the setting of resectable CLM.
Source: Frontiers in Oncology - August 9, 2023 Category: Cancer & Oncology Source Type: research
Predictors of Survival in Patients With Ischemic Stroke and Active Cancer: A Prospective, Multicenter, Observational Study
Conclusions The prognosis of patients with acute ischemic stroke and active cancer varied considerably depending on stroke mechanism, distant metastasis, and coagulation abnormalities. The present study confirmed that coagulation abnormalities were crucial in determining the prognosis of such patients.PMID:37489755 | DOI:10.1161/JAHA.123.029618
Source: Atherosclerosis - July 25, 2023 Category: Cardiology Authors: Yasufumi Gon Manabu Sakaguchi Hiroshi Yamagami Soichiro Abe Hiroyuki Hashimoto Nobuyuki Ohara Daisuke Takahashi Yuko Abe Tsutomu Takahashi Takaya Kitano Shuhei Okazaki Kenichi Todo Tsutomu Sasaki Satoshi Hattori Hideki Mochizuki SCAN Study Investigators Source Type: research
Mental Health and Quality of Life in Pulmonary Embolism: A Literature Review
Adv Respir Med. 2023 Apr 20;91(2):174-184. doi: 10.3390/arm91020015.ABSTRACTPulmonary embolismis an acute disease with chronic complications and, although it is not considered a chronic disease, it requires close follow-up. The scope of the present literature review is to decode the existing data concerning quality of life and the mental health impact of PE during the acute and long-term phases of the disease. The majority of studies reported impaired quality of life in patients with PE when compared to population norms, both in the acute phase and >3 months after PE. Quality of life improves over time, irrespectively o...
Source: Adv Data - April 27, 2023 Category: Epidemiology Authors: Niki Gkena Paraskevi Kirgou Konstantinos I Gourgoulianis Foteini Malli Source Type: research
Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions
This article summarizes the current knowledge about clonal hematopoiesis of indeterminate potential (CHIP), its association with cardiovascular disease (CVD), and other outcomes, pathogenesis, postulated mechanisms of various pathologies, current knowledge gaps, possible targets of intervention, and therapeutic implications.Recent FindingsRecently, a common age-related hematological entity known as CHIP has been identified as the independent risk factor for CVD. CHIP is defined as the presence of clonally expanded blood cells involving leukemogenic mutations without the evidence of malignancy. CHIP is known to increase the...
Source: Current Oncology Reports - March 16, 2023 Category: Cancer & Oncology Source Type: research
Venous thromboembolism in patients with idiopathic pulmonary fibrosis, based on nationwide claim data
CONCLUSION: Ischemic heart disease, ischemic stroke, and malignancy, especially lung cancer, were related to higher HR for VTE in IPF.PMID:36846942 | DOI:10.1177/17534666231155772
Source: Adv Data - February 27, 2023 Category: Epidemiology Authors: Jang Ho Lee Hoon Hee Lee Hyung Jun Park Seonok Kim Ye-Jee Kim Jae Seung Lee Ho Cheol Kim Source Type: research
Cumulative Incidence of Thromboembolism and Prognostic Impact of Stroke in < em > BRAF < /em > V600E-mutant Non-small-cell Lung Cancer
CONCLUSION: A substantial proportion of patients with BRAF V600E-mutant lung cancer experienced thromboembolism during their disease course. CRS of undetermined source may predict a worse prognosis in this population.PMID:36697098 | DOI:10.21873/anticanres.16237
Source: Cell Research - January 25, 2023 Category: Cytology Authors: Sho Yamada Akimasa Sekine Eri Hagiwara Yoko Onodera Erina Tabata Satoshi Ikeda Hideya Kitamura Tomohisa Baba Shigeru Komatsu Takashi Ogura Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
The effect of menopausal hormone therapy on the risk of melanoma and keratinocyte skin cancer: A systematic review and meta-analysis of observational studies
The re-analysis of Women's Health Initiative and the publication of data emerging from recent clinical trials data have restored the initial decline in the use of menopausal hormone therapy (MHT), due to adverse events, such as stroke and pulmonary embolism [1,2]. Nowadays, an increasing number of women treat their menopausal symptoms with hormonal therapies, which exhibit a better safety profile. However, the association of MHT with cancer development remains a potent drawback, with breast and endometrial cancer being the most frequently reported neoplasms [3,4].
Source: Maturitas - November 4, 2022 Category: Primary Care Authors: Konstantinos Lallas, Panagiotis Anagnostis, Patroklos Theocharis, Eirini Boureka, Athanasios Kyrgidis, Eleftherios Klonos, Georgios Papazisis, Zoe Apalla, Aimilios Lallas, Efstratios Vakirlis Tags: Review article Source Type: research
Neurovascular Manifestations of Iron-Deficient Anemia: Narrative Review and Practical Reflections through a Teaching Case
Conclusions: IDA is a common but treatable condition that, independently or synergically, may increase the risk of thrombotic events. The diagnostic and therapeutic approach has not yet been defined, and each case should be individually addressed in a pragmatic clinical road map.PMID:36294407 | DOI:10.3390/jcm11206088
Source: Clinical Lung Cancer - October 27, 2022 Category: Cancer & Oncology Authors: Marialuisa Zedde Giacomo Portaro Laura Ferri Francesco Cavallieri Manuela Napoli Claudio Moratti Fabrizio Piazza Franco Valzania Rosario Pascarella Source Type: research
